γιατί ορισμένες βακτηριακές λοιμώξεις υποτροπιάζουν μετά τη διακοπή της αντιβιοτικής αγωγής, ακόμη και όταν τα βακτήρια δεν εμφανίζουν κλασική αντοχή στα αντιβιοτικά?

Bottom line. Bacterial recurrence appears to be driven by phenotypic survival strategies such as the formation of antibiotic-tolerant persister cells and protective biofilms within intracellular sanctuary sites.

Phenomenological Distinction Between Resistance and Persistence

Bacterial populations produce rare, transient phenotypic variants known as "persisters" that are multidrug-tolerant but genetically identical to susceptible cells (PMID: 24766804; PMID: 23665232) «✓ PMID:24766804» «✓ PMID:23665232». Unlike antibiotic resistance, which involves inherited genetic modifications that increase the minimum inhibitory concentration (MIC), persistence is characterized by a biphasic killing curve where a subpopulation survives bactericidal exposure without a change in MIC (PMID: 30980069; PMID: 27080241) «✓ PMID:30980069» «✓ PMID:27080241». These persisters neither grow nor die in the presence of lethal agents, and upon antibiotic withdrawal, they can resume growth to re-establish a population as sensitive as the original inoculum (PMID: 15576765; PMID: 15308767) «✓ PMID:15576765» «✓ PMID:15308767». In biofilms, this tolerance can be 100 to 1,000 times higher than in corresponding planktonic cells (PMID: 25630538) «✓ PMID:25630538».

Molecular Effectors of Dormancy: TA Systems and the Stringent Response

The switch to a persistent state is frequently mediated by the activation of toxin-antitoxin (TA) modules and the (p)ppGpp-controlled stringent response (PMID: 28529326; PMID: 24766804) «✓ PMID:28529326» «✓ PMID:24766804». In Escherichia coli, stochastic accumulation of the alarmone (p)ppGpp triggers a signaling cascade involving polyphosphate and the Lon protease, which degrades antitoxins to release toxins that globally inhibit translation (PMID: 24766804) «✓ PMID:24766804». The hipBA module is a validated persistence factor; the HipA toxin functions as a serine/threonine kinase that phosphorylates and inactivates the glutamyl-tRNA synthetase GltX (PMID: 24343429; PMID: 32071324) «✓ PMID:24343429» «✓ PMID:32071324». This inactivation leads to the accumulation of uncharged tRNAs, further stimulating (p)ppGpp synthesis and reinforcing the dormant state (PMID: 24343429) «✓ PMID:24343429». Similarly, the SOS response induces the TisB toxin, a membrane-acting peptide that reduces the proton motive force (PMF) and ATP levels to induce dormancy (PMID: 20186264) «✓ PMID:20186264».

Metabolic Foundations of Tolerance and ATP Depletion

Current evidence suggests that metabolic target inactivation, rather than passive dormancy alone, governs persistence (PMID: 22096200) «✓ PMID:22096200». In Staphylococcus aureus, persister formation is linked to a stochastic drop in intracellular ATP levels, which decreases the activity of energy-dependent antibiotic targets such as DNA gyrase, topoisomerase, and RNA polymerase (PMID: 27398229) «✓ PMID:27398229». Experimental reduction of ATP using arsenate in E. coli has been shown to induce a 325-fold increase in persister formation and protect cells from fluoroquinolone-induced DNA fragmentation by slowing target-mediated reaction intermediates (PMID: 28174313) «✓ PMID:28174313». Active starvation responses also contribute by upregulating antioxidant defenses, such as catalase and superoxide dismutase, which limit the lethal hydroxyl radicals generated by many bactericidal classes (PMID: 22096200) «✓ PMID:22096200».

Biofilm Architecture and Intracellular Sanctuary Sites

Biofilms and intracellular niches provide physical and physiological protection that promotes recurrence. The extracellular polymeric substance (EPS) matrix acts as an ion-exchange resin that can delay the penetration of positively charged antibiotics like aminoglycosides (PMID: 25630538) «✓ PMID:25630538». Furthermore, the dense structure of a biofilm creates nutrient and oxygen gradients, forcing interior cells into a stationary-phase-like dormant state highly tolerant to drugs (PMID: 31295420; PMID: 25630538) «✓ PMID:31295420» «✓ PMID:25630538». In human urinary tract infections (UTIs), uropathogenic E. coli (UPEC) invade bladder epithelial cells to form intracellular bacterial communities (IBCs) with biofilm-like properties, protecting them from neutrophil phagocytosis (PMID: 18092884) «✓ PMID:18092884». These IBCs can evolve into quiescent intracellular reservoirs (QIRs) that remain viable for weeks, serving as seeds for relapsing infection as host cells turn over (PMID: 27499825; PMID: 18092884) «✓ PMID:27499825» «✓ PMID:18092884».

Clinical Pathogenesis and Relapse Dynamics

Clinical studies highlight the role of non-genetic survival in disease recalcitrance. In patients with cystic fibrosis, late isolates of Pseudomonas aeruginosa frequently evolve into high-persister (hip) mutants with no increase in classical drug resistance (PMID: 20935098) «✓ PMID:20935098». In human UTIs, recurrence is common, with 27% of women experiencing a second episode within six months of an index infection, often caused by a strain identical to the original (PMID: 27499825) «✓ PMID:27499825». Mycobacterium tuberculosis persists for months within granulomas in a dormant state, requiring extended chemotherapy to target these drug-tolerant populations (PMID: 28529326; PMID: 18466296) «✓ PMID:28529326» «✓ PMID:18466296». S. aureus bacteremia recurrence may also involve intracellular reservoirs in liver Kupffer cells that are poorly accessed by vancomycin (PMID: 27325887) «✓ PMID:27325887».

Contradictions and Evidence Gaps

There are significant species-specific differences in persistence mechanisms. While TA systems are central to E. coli persistence, deleting three active type II TA modules in S. aureus had no effect on persister levels (PMID: 27398229) «✓ PMID:27398229». Furthermore, the role of (p)ppGpp and the Lon protease is under debate, as some studies found no change in persister levels in E. coli strains lacking these components (PMID: 28174313) «✓ PMID:28174313». Mechanisms for persister resuscitation—how these cells switch back to a growing state—remain poorly understood and represent a major gap in the development of anti-recurrence therapies (PMID: 25630538; PMID: 28529326) «✓ PMID:25630538» «✓ PMID:28529326».

Research notebook

What are the molecular and metabolic mechanisms of bacterial persistence and how do they differ from genetic resistance?

Molecular mechanisms of persistence include the activation of toxin-antitoxin (TA) systems and metabolic shutdown driven by ATP depletion, which trigger a state of quiescence protected from antibiotic targets.

Status: verified • Confidence: medium

• Antibiotic persistence is defined as the ability of a subpopulation of bacteria to survive lethal antibiotic concentrations, whereas tolerance refers to the ability of the entire population to survive longer treatments; both are distinct from resistance, which involves a change in the minimum inhibitory concentration (MIC). (PMID 30980069, abstract)
• A consensus definition distinguishes resistance (inherited MIC increase) from tolerance (increased duration of survival for the whole population) and persistence (survival of a subpopulation), highlighting that these are transient phenotypic states. (PMID 27080241, abstract)
• Single-cell observations reveal that persisters are a pre-existing, non-growing subpopulation that emerges through a phenotypic switch rather than genetic mutation, allowing survival under antibiotic stress. (PMID 15308767, abstract)
• Toxin-antitoxin systems play a key role in persistence by releasing toxins that inhibit essential processes like translation or replication, thereby inducing growth arrest and dormancy. (PMID 26991085, abstract)
• In Staphylococcus aureus, persister formation is linked to a drastic reduction in intracellular ATP levels, which leads to the inactivation of antibiotic targets and increased survival. (PMID 27398229, abstract)
• Persistence mechanisms are diverse and include the (p)ppGpp-mediated stringent response, which couples metabolic stress to the induction of a dormant, antibiotic-tolerant state. (PMID 27980159, abstract)

How does antibiotic tolerance (transient phenotypic resistance) contribute to the survival of bacteria during treatment and subsequent relapse?

Antibiotic tolerance, often induced by starvation or slow growth, allows bacteria to survive treatment by slowing down the killing rate, which can lead to infection relapse once treatment is stopped and growth resumes.

Status: verified • Confidence: medium

• Tolerance facilitates the survival of bacterial populations under antibiotic pressure, providing a reservoir from which genetic resistance can subsequently evolve. (PMID 28183996, abstract)
• Active starvation responses, such as the stringent response, mediate tolerance by downregulating metabolic activities that antibiotics target, allowing survival in nutrient-limited environments like biofilms or host tissues. (PMID 22096200, abstract)
• The transient nature of tolerance means that surviving bacteria can resume growth after antibiotic withdrawal, leading to recurrent infections even if the bacteria remain genetically susceptible. (PMID 28529326, abstract)

What role do biofilms play in protecting non-resistant bacteria from antibiotic clearance and promoting recurrent infections?

Biofilms protect bacteria through a combination of physical shielding by the extracellular matrix, nutrient gradients that induce metabolic dormancy (persistence), and restricted antibiotic penetration.

Status: verified • Confidence: medium

• Biofilms enhance tolerance and persistence because the dense community structure creates nutrient and oxygen gradients, forcing cells in the deeper layers into a slow-growing or dormant state. (PMID 31295420, abstract)
• The extracellular polymeric substance (EPS) matrix of biofilms acts as a barrier that slows the diffusion of some antibiotics and provides a protected environment for persister cells to survive. (PMID 25630538, abstract)
• Mycobacterium tuberculosis can form biofilms containing drug-tolerant bacteria that are physically protected and metabolically distinct, contributing to the difficulty of clearing the infection. (PMID 18466296, abstract)

How do bacteria utilize intracellular niches or 'sanctuary sites' in the host to evade antibiotic action and cause recurrence?

Bacteria can evade antibiotics and cause recurrence by colonizing intracellular 'sanctuary sites' where they form specialized structures or enter a persistent state protected from the host immune system and antibiotic action.

Status: verified • Confidence: medium

• In human urinary tract infections, uropathogenic E. coli (UPEC) form intracellular bacterial communities (IBCs) within bladder epithelial cells, which protect them from neutrophils and antibiotic treatment, serving as a reservoir for recurrence. (PMID 18092884, abstract)
• Staphylococcus aureus can survive inside host cells, such as macrophages or osteoblasts, by forming persisters that are insensitive to antibiotics, leading to chronic or relapsing infections. (PMID 32366839, abstract)
• Salmonella induces the formation of non-replicating persister cells upon internalization by macrophages, using the host intracellular environment as a trigger for dormancy and survival. (PMID 24408438, abstract)

Which specific clinical examples (e.g., UTIs, Tuberculosis, Staphylococcus aureus) best illustrate recurrence without classical resistance?

Recurrent infections in UTIs, tuberculosis, and S. aureus infections are often driven by phenotypic survival mechanisms like persistence and biofilm formation rather than genetic resistance.

Status: verified • Confidence: medium

• Uropathogenic E. coli (UPEC) persist in the bladder wall by forming intracellular bacterial communities (IBCs), which are resistant to antibiotic clearance and cause recurrent UTIs. (PMID 18092884, abstract)
• Biofilm formation by UPEC on catheter surfaces or within the urothelium is a major factor in the persistence and recurrence of UTIs, even when the strains are susceptible to antibiotics in vitro. (PMID 16961644, abstract)
• Tuberculosis recurrence after treatment is frequently due to the presence of 'persister' cells that survive months of chemotherapy in a dormant state within granulomas. (PMID 28529326, abstract)
• Chronic Staphylococcus aureus infections, such as osteomyelitis, often recur due to the bacteria's ability to persist in small-colony variants (SCVs) or within intracellular niches in bone cells. (PMID 27325887, abstract)